Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer

Published:1999-01 Issue:1 Volume:6 Page:37-42
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Kobayashi Tetsuro,Koyama Hiroki,Oka Takahiro,Yasumura Tadaki,Kan Norimichi,Takatsuka Yuichi,Noguchi Masakuni,Morimoto Ken,Suzuki Takaichiro,Tobe Takayoshi,Mori Takesada

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF02966904.pdf

Reference21 articles.

1. Preiffer P, Cold S, Rose C: Cytotoxic treatment of metastatic breast cancer; Which drugs and drug combinations to use?Acta Oncol 31:219–224, 1992.

2. Mouridsen HT: Systemic therapy of advanced breast cancer.Drugs 44 (suppl 4): 17–28, 1992.

3. Bull JM, Tormey DC, Li SH,et al: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer 41:1649–1657, 1978.

4. Traum B, Hoogstrateu B, Kennedy A,et al: Adriamycin in combination for the treatment of breast cancer.Cancer 41:2078–2083, 1978.

5. Hortobagyi GN, Bodey GP, Buzdar AU,et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units; A prospective randomized study.J Clin Oncol 5:354–364, 1987.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP